# Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.

> **NCT02357966** · PHASE1,PHASE2 · COMPLETED · sponsor: **XBiotech, Inc.** · enrollment: 52 (actual)

## Conditions studied

- Staphylococcus Aureus Bacteremia

## Interventions

- **BIOLOGICAL:** 514G3 (2 mg/kg) plus standard IV antibiotic treatment
- **BIOLOGICAL:** 514G3 (10 mg/kg) plus standard IV antibiotic treatment
- **BIOLOGICAL:** 514G3 (40 mg/kg) plus standard IV antibiotic treatment
- **OTHER:** Placebo plus standard IV antibiotic treatment
- **BIOLOGICAL:** 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II
- **OTHER:** Placebo plus standard IV antibiotic treatment: Phase II

## Key facts

- **NCT ID:** NCT02357966
- **Lead sponsor:** XBiotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02357966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02357966, "Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02357966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*